Alpheus Medical Treats First Patients in First-In-Human Clinical Trial for Novel High-Grade Glioma Brain Cancer Treatment Milestone arrives as the company closes a $14 million follow-on Series A financing round to expand the clinical program for high-grade gliomas,...
FDA Grants Alpheus Medical Orphan Drug and Fast Track Designations for Novel Sonodynamic Therapy for Brain Cancer.
The company is currently enrolling patients in a multi-center Phase 1 clinical trial for the treatment of recurrent glioblastoma (GBM)
SAB to provide meaningful guidance as company begins first-in-human (FIH) clinical trial of their proprietary, non-invasive sonodynamic drug-device therapy system for recurrent high-grade gliomas.
Alpheus™ Medical, Inc, a privately held company developing a novel sonodynamic therapy (SDT) platform targeting solid body cancers, today announced it has closed $16M in Series A financing.